The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
Fore Biotherapeutics Appoints Michael Byrnes As Chief Financial Officer
PRIVATEAug 12, 2024•almost 2 years ago
Position
Chief Financial Officer
Company
Fore Biotherapeutics
Michael Byrnes
PhiladelphiaBiotechnologyHealth CareTherapeutics
Description
FORE Biotherapeutics has appointed Michael Byrnes as the new Chief Financial Officer. Mr. Byrnes brings over 20 years’ experience in the biotechnology industry and has a background and track record in both private and public companies.
Company Information
Company
Fore Biotherapeutics
Location
3675 MARKET STREET
Philadelphia, Pennsylvania, United States
About
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options.
PhiladelphiaBiotechnologyHealth CareTherapeutics